Pharmaron Stock Climbs 12.6% on $200M Eli Lilly GLP-1 Deal

Edgen Stock·Mar 12 2026, 02:58

Share to

Share to

Copy link

Key Takeaways

Pharmaron's stock value increased significantly after the company announced a major production and investment agreement with U.S. pharmaceutical giant Eli Lilly. The deal centers on Orforglipron, a promising oral GLP-1 drug for weight management, positioning Pharmaron as a key manufacturer in the lucrative obesity treatment market.

Strategic Partnership: Pharmaron will partner with Eli Lilly to produce Orforglipron, a first-in-class oral GLP-1 receptor agonist.
Major Investment: Eli Lilly is set to invest $200 million into Pharmaron to expand its technological and production capabilities.
Market Reaction: Pharmaron's shares surged 12.6% to $20.94 in Hong Kong trading following the announcement.

Shares Climb 12.6% on $200M Production Pact

Pharmaron's Hong Kong-listed shares (03759.HK) climbed 12.6% to $20.94 after the company announced a strategic production agreement with Eli Lilly (LLY.US). The stock reached an intraday peak of $21.06 on the news. The deal, confirmed via Pharmaron's official Weibo account, establishes a partnership for the manufacturing of Orforglipron, Eli Lilly's experimental oral small-molecule GLP-1 receptor agonist for weight loss and diabetes.

Deal Secures Key Role in High-Growth Obesity Drug Market

Under the terms of the agreement, Eli Lilly will invest $200 million into Pharmaron to support its technological development and manufacturing scale-up. This capital injection and partnership validate Pharmaron's capabilities and strategically position it within the high-demand supply chain for GLP-1 drugs. For Eli Lilly, the agreement helps de-risk and secure the production of a critical oral drug, aiming to accelerate its entry into the competitive global market for obesity treatments. The companies also indicated plans to potentially expand the cooperation in the future.